Chronic Myeloid Leukemia

Oncology·MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Prevalence

12.0 / 100K

Incidence

1.9 / 100K/yr

26 drugs in development·15 companies·16 clinical trials

Drug Pipeline by Phase

Approved(11)

Drug	Company
hydroxyurea	AVEDRO INC (AVDR)
imatinib	SUNSET ISLAND GROUP (SUN)
imatinib	Teva Pharmaceutical Industries Limited (TEVA)
imatinib	Amneal Pharmaceuticals, Inc. (AMRX)
imatinib	Aptinyx Inc. (APTX)
imatinib	Mylan II B.V. (MYL)
imatinib	DR REDDYS LABORATORIES LTD (RDY)
imkeldi	CG Oncology, Inc. (CGON)
nilotinib	Aptinyx Inc. (APTX)
nilotinib	Mersana Therapeutics, Inc. (MRSN)
nilotinib	DR REDDYS LABORATORIES LTD (RDY)

Phase 3(5)

Drug	Company
asciminib	Novartis AG (NVS)
bosutinib	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
nilotinib	GH Research PLC (GHRS)
ponatinib 30mg od	GH Research PLC (GHRS)
ponatinib 45mg od	GH Research PLC (GHRS)

Phase 2(4)

Drug	Company
abl001/asciminib	Novartis AG (NVS)
Asciminib	Novartis AG (NVS)
bcr-abl tyrosine kinase inhibitor	GH Research PLC (GHRS)
tern-701	Terns Pharmaceuticals, Inc. (TERN)

Phase 1(1)

Drug	Company
elvn-001	Enliven Therapeutics, Inc. (ELVN)

Preclinical(1)

Drug	Company
BCR-ABL TKI	Theseus Pharmaceuticals, Inc. (THRX)

Phase 4(4)

BioSniper tracks 26 drugs in development for Chronic Myeloid Leukemia across 15 companies.

There are 16 clinical trials targeting Chronic Myeloid Leukemia tracked by BioSniper.

The estimated prevalence of Chronic Myeloid Leukemia is approximately 12.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.